The U.S. stock market remains uncertain despite picking up in H1 and showing resiliency. This is in the wake of many key global concerns, such as China’s economic slowdown and dismal oil prices. And as we all know, an ambiguous stock market can, in one way or another, affect the marijuana industry.
The uncertainty of the upcoming election may also turn off multitudes of foreign investors. Panicking investors may just look beyond the U.S. and wait for the likes of Canada gives weed legalization a go. The latter is happening very soon.
Holding or buying a stock hoping that its price will appreciate in the future could also be the market’s strength. Smart investors who strongly believe in the commercial promise of medical marijuana do not dare short a stock. They hold stocks that aren’t as big as GW Pharmaceuticals Plc. GW Pharmaceuticals is the only nationally traded cannabis company in the country.
The smaller cannabis stocks like Insys Therapeutics can benefit from investors taking a long position in their stock. That is when their product becomes big on a nationwide scale down the road. For patient investors, the likes of Med-X, the first marijuana company to conduct an equity fund sourcing via the JOBS Act Regular A+, can be a good buy regardless of the stock market’s performance in the future.
Marijuana companies should turn their brands into the most palatable one not only in the country but also outside the U.S. It’s a good thing that they’re a little bit ahead of their would-be Canadian counterparts in terms of time, as the latter’s national legalization is still in the offing, and whose publicly traded weed firms are just existing through a court-mandated program.
Med-X, again, is doing a good job in establishing a brand that isn’t only strong but boasts of longevity, as it promises to produce only 100-percent research-based products built on years of R&D the company itself conducted. Such a branding could attract meticulous consumers, especially those who want to venture in the medical and food aspect of the industry.
Add to this Med-X’s goal of changing the public’s negative notion of medical marijuana, which it does through its publishing arm, The Marijuana Times. These two things give the company a very strong market position as investors don’t see such a branding—adherent of science and social advocate—on a daily basis.
The growth of cannabis firms in the U.S. will hinder the industry from reaching its utmost potential. This is because it could only sell its products in states where they aren’t prohibited. Unless the government allows a federally legal market, companies will remain burdened by various obstacles such as logistics, state law, and regulation nuances, and other factors, forcing them to just sell their products within the boundaries of their state. The absence of competition could hinder the possibility of better prices in the future, which directly affects stock prices.
Economists believe that the cannabis market has a lot of promise and can withstand a vulnerable US stock market. After all, it can surpass the $7 million mark before the year ends. Still, the absence of a national policy and a federal support can just make it a mediocre segment.
There’s no doubt about the market’s growth if one would look at it as a statewide industry. Yet federalized prohibition can make it more enticing even to investors as in the case of Canada. Through this, smaller brands can even dream of competing with GW or other Big Pharma companies. They could also become a market leader.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
Roche signs its new diabetes business manager in Spain to Isdin
The company Roche Diabetes Care Spain, part of the Swiss pharmaceutical group, has appointed Josep Maria Vallmajó to hold the...
Major reasons why your website might not be attracting customers
In 2016, the number of business websites had almost doubled from 900 million to nearly 1.7 billion. Whatever your marketing...
Savills IM refinances two Italian assets with one of the first green loans in Italy
One of the first green loans in Italy will refinance the retail park in Fidenza (Parma) and the U4 office...
4 tips to market your small business locally
Whether you’ve recently started a small business or have pivoted your sales tactics for your company because of COVID-19, you’re...
Bitcoin revolution by integration with PayPal
The integration of Bitcoin with PayPal is probably one of the most important news for the entire crypto industry in...
Africa5 days ago
Why countries in southern Africa could become leaders in the cannabis sector
Featured6 days ago
How the coronavirus pandemic impacted the German Fintech sector
Featured6 days ago
Why is the stock market up?
Featured6 days ago
What’s the problem with the Dow Jones? Maybe it’s overvalued